Yahoo Web Search

Search results

1. • 

     The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022

     Investor's Business Daily· 2 years ago

     Bristol Myers Squibb reaffirmed expectations for a $10 billion pitfall from its generics-facing...

2. • 

     Biden targets diabetes drug Jardiance, blood thinner Eliquis, and 8 others for controversial...

     Fortune via Yahoo Finance· 8 months ago

     The move is expected to cut costs in a few years for some patients but faces litigation from the...

3. • 

     Is prescription copay assistance contributing to rising drug prices? Why buyers should beware.

     USA TODAY via Yahoo Finance· 1 year ago

     When Beth Waldron got a letter from her health insurance provider last year that her blood thinner...

4. • 

     Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down

     Zacks via Yahoo Finance· 2 years ago

     Bristol-Myers Squibb Company BMY reported first-quarter 2022 earnings of $1.96 per share, which beat...

5. • 

     Bristol Myers 1st-quarter sales up on Eliquis, Opdivo

     Reuters via Yahoo Finance· 2 years ago

     Drugmaker Bristol Myers Squibb posted slightly better-than-expected first-quarter earnings on Friday...

6. • 

     These 10 Drugs Should Save Medicare Patients Millions After Price Negotiations

     Verywell Health via Yahoo News· 8 months ago

     For the first time, the federal government will negotiate with drug makers in order to reduce the...

7. • 

     Bristol Myers looks to new CEO as competition from generic drugs heats up

     Reuters via Yahoo Finance· 12 months ago

     (Reuters) -Bristol Myers Squibb said on Wednesday evening its CEO Giovanni Caforio would step down...

8. • 

     Bayer ends large blood thinner trial for ‘inferior efficacy’

     BioPharma Dive via Yahoo Finance· 5 months ago

     Bayer is stopping a large clinical trial testing its experimental blood thinner asundexian in people...

9. • 

     Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?

     Zacks via Yahoo Finance· 1 year ago

     Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental...

10. • 

      Bristol Myers Relies On 'Mature' Products For Narrow Quarterly Beat

      Investor's Business Daily· 1 year ago

      Most of Bristol Myers Squibb's "mature" products delivered commanding third-quarter performances, an...